FMS FMS
Company Profile ↓Company Overview
FMS (FMS) is a publicly traded company listed on with a market capitalization of $7.01B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 13.3% per year over the last five years.
Trades at an undemanding P/E of 14.2.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $19.63B (+1.5% YoY); net profit $978.37M.
- Trailing 12 Months Year-on-year growth — revenue +1.5%, earnings +81.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.4%, profit CAGR 13.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.39% |
| 1 Year: | 1.51% |
Compounded Profit Growth
| 5 Years: | 13.26% |
| 1 Year: | 81.88% |
Stock Price Performance
| 1 Year: | -0.35% |
| 6 Months: | +8.15% |
| 3 Months: | +23.10% |
| 1 Month: | -1.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross10d ago
- RSI (14)46.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 13.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 4.88B | 4.79B | 4.88B | 5.07B | 4.61B |
| Cost of Revenue | 3.70B | 3.58B | 3.64B | 3.68B | 3.43B |
| Gross Profit | 1.18B | 1.21B | 1.24B | 1.39B | 1.18B |
| Operating Expenses | 802.25M | 819.96M | 740.50M | 839.39M | 803.94M |
| Operating Income | 381.73M | 394.40M | 501.72M | 548.98M | 375.56M |
| EBITDA | 740.73M | 822.37M | 852.92M | 981.03M | 763.76M |
| Interest Expense | 95.72M | 96.58M | 93.10M | 99.02M | 93.30M |
| Pretax Income | 250.65M | 350.55M | 402.57M | 508.46M | 207.52M |
| Tax Provision | 61.05M | 78.26M | 75.22M | 106.44M | 42.75M |
| Net Income | 151.22M | 225.27M | 274.80M | 327.08M | 117.53M |
| Diluted EPS | 0.26 | 0.39 | 0.47 | 0.57 | 0.21 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 19.40B | 19.45B | 19.34B | 19.63B |
| Cost of Revenue | 14.50B | 14.53B | 14.58B | 14.60B |
| Gross Profit | 4.89B | 4.93B | 4.76B | 5.03B |
| Operating Expenses | 3.44B | 3.45B | 3.29B | 3.20B |
| Operating Income | 1.45B | 1.48B | 1.47B | 1.83B |
| EBITDA | 3.42B | 3.21B | 3.21B | 3.40B |
| Interest Expense | 360.14M | 424.64M | 407.04M | 384.41M |
| Pretax Income | 1.22B | 1.03B | 1.06B | 1.51B |
| Tax Provision | 324.95M | 300.56M | 316.06M | 320.97M |
| Net Income | 673.40M | 499.00M | 537.91M | 978.37M |
| Diluted EPS | 1.15 | 0.85 | 0.92 | 1.68 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 35.75B | 33.93B | 33.57B | 31.00B |
| Current Assets | - | 8.20B | 8.70B | 7.92B | 7.90B |
| Cash & Equivalents | - | 1.27B | 1.38B | 1.15B | 1.58B |
| Inventory | - | 2.30B | 2.18B | 2.07B | 2.14B |
| Receivables | - | 3.67B | 3.43B | 3.40B | 3.16B |
| Total Liabilities | - | 20.30B | 19.10B | 17.80B | 16.72B |
| Current Liabilities | - | 6.47B | 6.11B | 5.66B | 6.25B |
| Long Term Debt | - | 7.17B | 6.96B | 6.26B | 5.69B |
| Total Debt | - | 13.19B | 12.05B | 10.98B | 10.80B |
| Total Equity | - | 13.99B | 13.62B | 14.58B | 13.31B |
| Shares Outstanding | - | 293.41M | 293.41M | 293.41M | 293.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.17B | 2.63B | 2.39B | 2.68B |
| Investing Cash Flow | - | -734.73M | -544.23M | -84.94M | -722.53M |
| Financing Cash Flow | - | -1.62B | -1.86B | -2.57B | -1.40B |
| Capital Expenditure | - | -723.99M | -684.60M | -699.36M | -915.37M |
| Free Cash Flow | - | 1.44B | 1.94B | 1.69B | 1.77B |
| Net Change in Cash | - | -184.71M | 226.04M | -268.10M | 555.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 25.2% | 25.3% | 24.6% | 25.6% |
| Operating Margin % | 7.5% | 7.6% | 7.6% | 9.3% |
| Net Margin % | 3.5% | 2.6% | 2.8% | 5.0% |
| ROE % | 4.8% | 3.7% | 3.7% | 7.4% |
| ROCE % | 5.0% | 5.3% | 5.3% | 7.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FMS
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF
Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and HVHDF across large patient populations, …
Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns
Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the cheap side rather than as a fully valued t…
Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?
Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, reshaping leadership oversight of its globa…
Fresenius Medical Care AG & Co. KGaA Q2 2026 Earnings Call Summary
Moby summary of Fresenius Medical Care AG & Co. KGaA's Q2 2026 earnings call
Fresenius Medical Care AG (FMS) (Q2 2026) Earnings Call Highlights: Strong Profit Growth and ...
FMS delivers 23% operating income growth and margin expansion, while navigating US referral headwinds and TDAPA roll-off.
FMS — Frequently Asked Questions
What is the current share price of FMS?
As of 2026-08-05 17:25 PDT, FMS trades at $23.89 on NASDAQ/NYSE. Its 52-week range is $19.41 to $26.35.
What is the market capitalisation of FMS?
FMS has a market capitalisation of $7.01B on NASDAQ/NYSE.
What is the P/E ratio of FMS?
FMS trades at a trailing price-to-earnings (P/E) ratio of 14.22. Its price-to-book (P/B) ratio is 0.53.
What is the return on equity (ROE) of FMS?
FMS has a return on equity (ROE) of 7.35%. Its return on capital employed (ROCE) is 7.38%.
Is FMS a good stock to buy?
This page provides a data-driven analysis of FMS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.